Sponsored by AstraZeneca and Daiichi Sankyo
This activity is not certified for credit.
Friday, September 7
The program objective is to gain in-depth knowledge of MOVANTIK, the first once-daily, oral therapy in its class specifically designed for the treatment of OIC in adult patients with chronic non-cancer pain.
Jeffrey Gudin, MD
Posted on August 24, 2018